La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

North China Pharmaceutical Company.Ltd Gestione

Gestione criteri di controllo 4/4

We currently do not have sufficient information about the CEO.

Informazioni chiave

Xin Yan Liu

Amministratore delegato

CN¥262.4k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	3yrs
Proprietà del CEO	n/a
Durata media del management	3yrs
Durata media del Consiglio di amministrazione	4.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

The Market Doesn't Like What It Sees From North China Pharmaceutical Company.Ltd's (SHSE:600812) Revenues Yet

Apr 26

AMMINISTRATORE DELEGATO

Xin Yan Liu (54 yo)

3yrs

Mandato

CN¥262,400

Compensazione

Mr. Xin Yan Liu is General Manager and Director of North China Pharmaceutical Company Ltd. since August 13, 2021 and served as its Deputy General Manager.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Xin Yan Liu	GM & Director	3yrs	CN¥262.40k	Nessun dato
Jianjun Li	CFO & Chief Accountant	3yrs	CN¥200.40k	Nessun dato
Zhi Shan Chang	Deputy GM & Secretary	8.4yrs	CN¥200.40k	Nessun dato

3.0yrs

Durata media

53yo

Età media

Gestione esperta: 600812's management team is considered experienced (3 years average tenure).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Xin Yan Liu	GM & Director	3yrs	CN¥262.40k	Nessun dato
Guangcheng Pan	Independent Director	5.3yrs	CN¥71.40k	Nessun dato
Xiaohan Liu	Independent Director	5.3yrs	CN¥71.40k	Nessun dato
Yao Cao	Director	5.9yrs	CN¥200.40k	Nessun dato
Fan Li	Supervisor	5.9yrs	Nessun dato	Nessun dato
Jigang Xie	Independent Director	3.3yrs	CN¥71.40k	Nessun dato
Demin Zhou	Independent Director	5.3yrs	CN¥71.40k	Nessun dato
Rentao Song	Director	1.4yrs	Nessun dato	Nessun dato
Wei Lv	Chairman of the Supervisory Board	1.8yrs	Nessun dato	Nessun dato
Wenzan Gao	Supervisor	1.8yrs	Nessun dato	Nessun dato

4.3yrs

Durata media

55yo

Età media

Consiglio di amministrazione esperto: 600812's board of directors are considered experienced (4.3 years average tenure).

North China Pharmaceutical Company.Ltd Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

North China Pharmaceutical Company.Ltd, Annual General Meeting, Jun 26, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Second quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.012 in 2Q 2023)

North China Pharmaceutical Company.Ltd to Report First Half, 2024 Results on Aug 14, 2024

North China Pharmaceutical Company.Ltd, Annual General Meeting, Jun 26, 2024

The Market Doesn't Like What It Sees From North China Pharmaceutical Company.Ltd's (SHSE:600812) Revenues Yet

First quarter 2024 earnings released: EPS: CN¥0.011 (vs CN¥0.003 in 1Q 2023)

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: CN¥0.003 (vs CN¥0.40 loss in FY 2022)

North China Pharmaceutical Company.Ltd to Report Q1, 2024 Results on Apr 26, 2024

Now 21% undervalued after recent price drop

North China Pharmaceutical Company.Ltd to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.003 in 3Q 2022)

North China Pharmaceutical Company.Ltd to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.012 (vs CN¥0.011 in 2Q 2022)

Now 21% undervalued after recent price drop

North China Pharmaceutical Company.Ltd to Report First Half, 2023 Results on Aug 19, 2023

First quarter 2023 earnings released: EPS: CN¥0.003 (vs CN¥0.008 in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released

First quarter 2022 earnings released: EPS: CN¥0.008 (vs CN¥0.035 loss in 1Q 2021)

Less than half of directors are independent

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.028 in 2Q 2020)

First quarter 2021 earnings released: CN¥0.035 loss per share (vs CN¥0.039 profit in 1Q 2020)

New 90-day low: CN¥8.48

Investor sentiment deteriorated over the past week

New 90-day low: CN¥9.80

New 90-day low: CN¥10.25

Jizhong Energy Resources Co., Ltd. (SZSE:000937) completed the acquisition of a 10% stake in North China Pharmaceutical Company. Ltd (SHSE:600812) from Jizhong Energy Group Company Limited.

Third quarter earnings released

New 90-day low: CN¥11.53

Third quarter earnings released

North China Pharmaceutical Company. Ltd to Report Q3, 2020 Results on Oct 23, 2020

First half earnings released

New 90-day high - CN¥15.07

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media